Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a daily vitamin and sunshine curb Kids' nearsightedness?

NCT ID NCT03552016

Prevention Sponsor: University of Missouri-Columbia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 24, 2026 · Last updated Aug 25, 2026 · Updated 1 time

Summary

This study tests whether taking vitamin B2 (riboflavin) daily and spending time outdoors in sunlight can slow the progression of myopia (nearsightedness) in children aged 6 to 12. Participants will be randomly assigned to receive different doses of riboflavin or a placebo, and all will be encouraged to play outside. Over three years, researchers will measure changes in the eye's refraction and axial length to see if the combination helps prevent the eye from becoming more nearsighted.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Oral riboflavin (vitamin B2) combined with outdoor sunlight exposure
What this could lead to
If effective, this could offer a simple, non-invasive way to slow the progression of nearsightedness in children, potentially reducing the need for stronger glasses or future eye problems.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not be conclusive. The effectiveness of riboflavin and sunlight for myopia is uncertain, and there are potential risks like sun exposure or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Started

Oct 2018

Finished

Dec 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 12 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy children ages 6-12 years old with myopia more than 0.50 D and astigmatism no more than 1.5 D. * Caretakers who choose to enroll their child in the study must agree to participate in the study on their own will after knowledge of potential alternatives (spectacle correction, orthokeratology, atropine eye drops, etc.) are explained to the patient's caretaker. Exclusion Criteria: * Known allergy to riboflavin * Birth history of premature birth * Developmental delay or other neurological or mental conditions * Major systemic health problems * Significant anisometropia more than 1.5 Diopters * Any other eye condition which may complicate interpretation of data including: congenital glaucoma, congenital cataract, ectatic corneal condition, amblyopia or strabismus.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Axial myopia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myopia refractive error

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Axial myopia Refractive errors

Contacts and locations

Locations

  • Virginia Commonwealth University

    Richmond, Virginia, 23298, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.